

February 19, 2026
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

**SymBio Receives Notice of Patent Grant in the U.S. for IV BCV Use Patent,
Securing Patent Exclusivity Through 2044**

Tokyo, Japan, February 19, 2026 – SymBio Pharmaceuticals Limited (hereinafter “SymBio” or the “Company”) today announced that the United States Patent and Trademark Office has granted U.S. Patent No. 12,544,392 covering the use of intravenous brincidofovir (IV BCV) for the treatment of adenovirus infection following hematopoietic stem cell transplantation. As a result, patent exclusivity in the United States is secured through 2044. In Europe, the European Patent Office (EPO) has issued a Decision to Grant for the corresponding European patent. In Japan, the corresponding patent has already been granted, securing patent exclusivity in Japan through 2043.

This patent covers clinical use parameters of IV BCV for adenovirus infection following hematopoietic stem cell transplantation, including dosing and administration. The patent is intended to protect use information that is expected to be contained in the product labeling (package insert) following marketing approval, and is expected to afford strong legal protection. Together with the formulation patents for IV BCV, SymBio has secured periods of patent exclusivity in Japan, the United States, and Europe.

For details of the ongoing Phase 3 clinical trial of BCV for adenovirus infection, please refer to the Company’s press release dated June 30, 2025 ([SymBio Submits Clinical Trial Application for a Phase 3 Global Study Evaluating IV Brincidofovir for the Treatment of Adenovirus Infection after HSCT](#)).

SymBio will continue to secure indication-specific use patents aligned with real-world clinical practice (including items to be reflected in the package insert) to

extend and strengthen exclusivity by indication and maximize the business value of IV BCV.

SymBio remains committed to accelerating the development and commercialization of BCV to bring it to patients as quickly as possible to address critical unmet medical needs.

This matter is not expected to have a material impact on the Company's consolidated financial results for the fiscal year ending December 2026.

Notes

Overview of Use Patent for IV BCV in Adenovirus Indication

- Patent holder: SymBio Pharmaceuticals Limited
- Term of validity:
 - Japan: August 7, 2043 (Patent No. 7,417,339)
 - U.S.: May 6, 2044 (Patent No. 12,544,392)
- Scope: Clinical regimen (dosing and administration) of IV BCV for the treatment of adenovirus infection

Overview of Formulation Patents for IV BCV

- Jurisdictions and patent numbers:
 - Japan: Patent Nos. 6,878,473; 7,221,485; 7,407,984
 - Europe: Patent No. 3,474,822
 - U.S.: Patent No. 12,485,131
- Patent holder: Emergent Biodefense Operations Lansing LLC
- Term of validity: June 28, 2037
- Scope: Formulation of brincidofovir for intravenous administration

BCV Business Strategy Based on Three Therapeutic Pillars

Since obtaining the global license for BCV in September 2019, SymBio has advanced collaborative research with world-class institutions to unlock IV BCV's potential across three strategic therapeutic areas where the Company is currently focusing its development resources: (1) viral infections following hematopoietic stem cell transplantation; (2) hematologic and solid tumors; and (3) neurodegenerative diseases. SymBio has filed eight patent applications to date,

and by layering these IP initiatives with regulatory strategies such as Orphan Drug Designation (ODD), the Company aims to maximize the value of its pipeline.